Ji-Bo Kang,Lu Chen,Xue-Jiao Leng,Jing-Jing Wang,Yang Cheng,Shi-Han Wu,Yi-Yuan Ma,Li-Jin Yang,Yu-Hao Cao,Xiao Yang,Zhen-Jiang Tong,Jia-Zhen Wu,Yi-Bo Wang,Hai Zhou,Jia-Chuan Liu,Ning Ding,Wei-Chen Dai,Yan-Cheng Yu,Xin Xue,Shan-Liang Sun,Xiao-Bin Dai,Liang Chang,Xiao-Long Wang,Nian-Guang Li,Zhi-Hao Shi

Abstract:Fms-like tyrosine kinase 3 (FLT3) mutation has been strongly associated with increased risk of relapse, and the irreversible covalent FLT3 inhibitors had the potential to overcome the drug-resistance. In this study, a series of simplified 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine derivatives containing two types of Michael acceptors (vinyl sulfonamide, acrylamide) were conveniently synthesized to target FLT3 and its internal tandem duplications (ITD) mutants irreversibly. The kinase inhibitory activities showed that compound C14 displayed potent inhibition activities against FLT3 (IC 50 = 256 nM) and FLT3-ITD by 73% and 25.34% respectively, at the concentration of 1 μM. The antitumor activities indicated that C14 had strong inhibitory activity against the human acute myeloid leukemia (AML) cell lines MOLM-13 (IC 50 = 507 nM) harboring FLT3-ITD mutant, as well as MV4-11 (IC 50 = 325 nM) bearing FLT3-ITD mutation. The biochemical analyses showed that these effects were related to the ability of C14 to inhibit FLT3 signal pathways, and C14 could induce apoptosis in MV4-11 cell as demonstrated by flow cytometry. Fortunately, C14 showed very weak potency against FLT3-independent human cervical cancer cell line HL-60 (IC 50 > 10 μM), indicating that it might have no off-target toxic effects. In light of these data, compound C14 represents a novel covalent FLT3 kinase inhibitor for targeted therapy of AML.

Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine Derivatives As Type-II Inhibitors of FLT3 Selective Against C-Kit

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Design, synthesis, and evaluation of pyrido.[3,4–b]pyrazin-2(1 H )-one derivatives as potent FLT3 inhibitors

Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/stem Cell Factor Receptor (Flt3/c-Kit) Inhibitor for the Treatment of Acute Myelogenous Leukemia

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

Design and Synthesis of Selective FLT3 Inhibitors Via Exploration of Back Pocket II

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Rational Design of 4-((6-phenoxypyrimidin-4-yl)amino)-n-(4-(piperazin-1-yl)phenyl)-1h-pyrazole-3-carboxamide (LT-540-717) As Orally Bioavailable FLT3 Inhibitor

Design, synthesis, and biological evaluation of a series of indolone derivatives as novel FLT3 inhibitors for the treatment of acute myeloid leukemia

Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia.

Computer Aided Drug Discovery of Highly Ligand Efficient, Low Molecular Weight Imidazopyridine Analogs As FLT3 Inhibitors.

Identification of 2-Aminopyrimidine Derivatives As FLT3 Kinase Inhibitors with High Selectivity over C-Kit.

Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1H-Pyrazole-3-Carboxamide Derivatives and Their Potent Activity Against Acute Myeloid Leukemia (AML)

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

Discovery of 1-(4-(4-amino-3-(4-(2-morpholinoethoxy)phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) As a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia

Discovery and structure − activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)